High cardiovascular drug costs may limit access to patients

 - Money Pour test
Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

An FDA advisory panel recommended the approval of alirocumab and evolocumab last week, and the cardiovascular medications are expected to be approved this summer. However, the drugs may cost up to $10,000 per year and may be too expensive for some patients, USA Today reports.